Evidence map›Paper›PMID 28542029›Full record

ArticleCritical care medicine2017

The Impact of the Sepsis-3 Septic Shock Definition on Previously Defined Septic Shock Patients.

Sarah A Sterling, Michael A Puskarich, Andrew F Glass, Faheem Guirgis, Alan E Jones

Abstract readMulticenter Study
In one paragraph

Article in Critical care medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Continuous versus Intermittent Hydrocortisone for the Treatment of Septic Shock: A Systematic Review and Meta-Analysis.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2026
    Pooled it
  2. All-cause mortality in cancer patients treated for sepsis in intensive care units: a systematic review and meta-analysis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022
    Pooled it
  3. Trial
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Molecular mechanisms in septic shock (Review).Experimental and therapeutic medicine · 2021
    Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Sarah A Sterling1Department of Emergency Medicine, University of Mississippi Medical Center, Jackson, MS. 2Department of Emergency Medicine, University of Florida College of Medicine-Jacksonville, Jacksonville, FL.
Michael A Puskarich
Andrew F Glass
Faheem Guirgis
Alan E Jones

Funding

Tracking and Evaluation CoreU54GM115428 · NIGMS · UNIVERSITY OF MISSISSIPPI MED CTR · PI LIRETTE, SETH · 2016 to 2025
$38.2M
Together: Transforming and Translating Discovery to Improve HealthKL2TR001429 · NCATS · UNIVERSITY OF FLORIDA · PI GUIRGIS, FAHEEM W, LEEUWENBURGH, CHRISTIAAN · 2015 to 2023
$5.5M
L-carnitine Treatment for Vasopressor Dependent Septic ShockR01GM103799 · NIGMS · UNIVERSITY OF MISSISSIPPI MED CTR · PI JONES, ALAN E · 2012 to 2016
$3.1M
Platelet activation in septic shockK23GM113041 · NIGMS · UNIVERSITY OF MISSISSIPPI MED CTR · PI PUSKARICH, MICHAEL A. · 2015 to 2018
$763k
The Role of Dysfunctional HDL in SepsisK23GM115690 · NIGMS · UNIVERSITY OF FLORIDA · PI GUIRGIS, FAHEEM W · 2016 to 2019
$699k
NCATS NIH HHS KL2 TR001429NIGMS NIH HHS K23 GM113041NIGMS NIH HHS K23 GM115690NIGMS NIH HHS R01 GM103799NIGMS NIH HHS U54 GM115428
6 · The paper itself

Abstract

objectiveThe Third International Consensus Definitions Task Force (Sepsis-3) recently recommended changes to the definitions of sepsis. The impact of these changes remains unclear. Our objective was to determine the outcomes of patients meeting Sepsis-3 septic shock criteria versus patients meeting the "old" (1991) criteria of septic shock only.

designSecondary analysis of two clinical trials of early septic shock resuscitation.

settingLarge academic emergency departments in the United States. PATIENTS: Patients with suspected infection, more than or equal to two systemic inflammatory response syndrome criteria, and systolic blood pressure less than 90 mm Hg after fluid resuscitation.

interventionsPatients were further categorized as Sepsis-3 septic shock if they demonstrated hypotension, received vasopressors, and exhibited a lactate greater than 2 mmol/L. We compared in-hospital mortality in patients who met the old definition only with those who met the Sepsis-3 criteria. MEASUREMENTS AND MAIN

resultsFour hundred seventy patients were included in the present analysis. Two hundred (42.5%) met Sepsis-3 criteria, whereas 270 (57.4%) met only the old definition. Patients meeting Sepsis-3 criteria demonstrated higher severity of illness by Sequential Organ Failure Assessment score (9 vs 5; p < 0.001) and mortality (29% vs 14%; p < 0.001). Subgroup analysis of 127 patients meeting only the old definition demonstrated significant mortality benefit following implementation of a quantitative resuscitation protocol (35% vs 10%; p = 0.006).

conclusionIn this analysis, 57% of patients meeting old definition for septic shock did not meet Sepsis-3 criteria. Although Sepsis-3 criteria identified a group of patients with increased organ failure and higher mortality, those patients who met the old criteria and not Sepsis-3 criteria still demonstrated significant organ failure and 14% mortality rate.

Indexed as

Blood PressureClinical Trials as TopicEmergency Service, HospitalHospital MortalityHumansLactic AcidOrgan Dysfunction ScoresSeverity of Illness IndexShock, SepticSystemic Inflammatory Response SyndromeUnited StatesVasoconstrictor AgentsLactic AcidVasoconstrictor Agents

Identifiers

PMID28542029
PMCPMC5693309

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.